| Autor: |
M G, Poluéktov, Ia I, Levin, A N, Boĭko, A A, Skoromets, G N, Bel'skaia, A V, Gustov, B M, Doronin, I E, Poverennova, N N, Spirin, E Z, Iakupov |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 112(9) |
| ISSN: |
1997-7298 |
| Popis: |
The results of the multicenter open-label observational study of the efficacy and safety of the Melaxen (melatonin) for the treatment of disordered sleep in patients with chronic cerebral ischemia are presented. 2062 patients were studied with the use of subjective psychometric scales: subjective sleep characteristics scale, sleep apnea screening questionnaire, Epworth sleepiness scale, hospital anxiety and depression scale. Mean age of patients was 55.7±9.0 years, there were 74.1% females and 25.9% males. Melaxen was given in dosage of 3 mg. before sleep for 24 days. The use of Melaxen leads to the increase of subjective sleep quality by the subjective sleep characteristics scale from 19.7±3.1 points to и 22.7±3.4 points on day 14 and 22.7±3.4 on day 24 (differences are significant at p0.0001). There was the decrease of the relative number of patients with frequent night awakenings, prolonged sleep latency, short night sleep, poor quality of morning awakening and multiple bothering dreams. Authors conclude that the use of Melaxen in dosage of 3 mg before sleep is effective and safe insomnia treatment in patients with chronic cerebral ischemia. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
